Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

Protein kinase CK2 has emerged as an attractive therapeutic target in acute myeloid leukemia (AML), an advent that becomes particularly relevant since the treatment of this hematological neoplasia remains challenging. Here we explored for the first time the effect of the clinical-grade peptide-based...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biomedicines
Egile Nagusiak: Rosales, Mauro, Pérez, George V., Ramón, Ailyn C., Cruz, Yiliam, Rodríguez-Ulloa, Arielis, Besada, Vladimir, Ramos, Yassel, Vázquez-Blomquist, Dania, Caballero, Evelin, Aguilar, Daylen, González, Luis J., Zettl, Katharina, Wiśniewski, Jacek R., Yang, Ke, Perera, Yasser, Perea, Silvio E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301452/
https://ncbi.nlm.nih.gov/pubmed/34356831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines9070766
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak